Skip to main content

News

From Psoriasis to PsA: Who and Why?

The number of patients with psoriasis who go on to develop psoriatic arthritis (PsA) is considerably higher than has previously been estimated, a prospective cohort study found.

Psoriasis May Not Be a Risk for CV Events

Patients with psoriatic skin and joint disease are uniquely susceptible to multiple comorbidities, obesity and possibly more cardiovascular risks. In rheumatoid arthritis, the increased CV risk and CV events have been closely aligned with inflammation and disease activity.

AMA Proposes Ban on Television Drug Ads

The American Medical Association has called for a ban on direct-to-consumer (DTC) advertising for prescription drugs and medical devices, noting these forms of advertising drive up health care costs and often mislead the public.

SB4 - A Second Biosimilar Up For Review in Europe

A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.

Alcohol and Methotrexate - What Do You Advise?

What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?

Tocilizumab & Abatacept Effective in Giant Cell Arteritis

Giant cell arteritis (GCA) is a medium and large vasculitis, wherein only glucocorticoids (GC) treatment has been the mainstay of therapy. As many will require prolonged treatment, the hazards of GC are well known, lead to substantial toxicity and morbidity.

Surviving Infection on DMARDs or Biologics

Sepsis is a dangerous and potentially fatal consequence of serious infections (SIE), particularly in susceptible populations such as the elderly and immunosuppressed. Published evidence points toward the potential role of TNF in development of sepsis.

Are Guidelines Worth the Cost?

A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.

Pharmacy Benefit Managers at Odds with Specialty Pharmacies

Reuters and the Wall Street Journal have reported that the largest U.S. pharmacy benefit managers (PBM) of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices.

Hypertension Increased in Psoriasis Treated with NSAIDs, Cyclosporine or Steroids

Psoriasis and psoriatic arthritis patient have significantly higher rates of comorbidity, including hypertension (HTN). This population-based, nested case–control study analyzed an inception psoriasis cohort from Taiwan's National Health Insurance Research Database between 2000–2010.

Biology of Bone Remodeling in Psoriatic Disease

Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.

Is Baricitinib Really Better Than Adalimumab in RA: Trial Results Reviewed

Dr. Peter Taylor and colleagues presented their results of the 52-week BEAM trial wherein baricitinib (a JAK 1, 2 inhibitor) was compared to adalimumab in both clinical and radiographic outcomes. This was the most viewed abstract online at the ACR website.

×